AZ puts Brilinta up for another head-to-head fight with Plavix

AstraZeneca doesn't shy from a challenge. The drugmaker ($AZN) has launched a study comparing its clot-fighter Brilinta with the standard bloodthinner treatment Plavix, in patients with peripheral artery disease. It's just the latest head-to-head study pitting Brilinta against Plavix, which recently went generic. Story